Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Reaffirms Their Sell Rating on Novavax (NVAX)

Tipranks - Tipranks - Fri Jan 16, 5:36AM CST

Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on Novavax today and set a price target of $6.00.

Claim 70% Off TipRanks Premium

Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Crispr Therapeutics AG, and Agios Pharma. According to TipRanks, Stranahan has an average return of 8.7% and a 53.72% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for Novavax with a $10.00 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Novavax’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $70.45 million and a GAAP net loss of $202.38 million. In comparison, last year the company earned a revenue of $84.51 million and had a GAAP net loss of $121.3 million

Read More on NVAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).